title: [Conn's syndrome. Study of systemic cardiovascular hemodynamics after medical treatment with spironolactone and after surgical treatment].
abstract: OBJECTIVE
  Assess hemodynamic effect of Conn's syndrome in order to better prepare patients for surgical resection of their adenoma.
  
  
  METHODS
  Hemodynamic investigations were conducted before any treatment in 13 patients with Conn's syndrome. Results were compared with those in 13 control subjects with permanent primary hypertension. In the 13 patients with Conn's syndrome, the same hemodynamic parameters were studied in 13 after drug therapy using spironolactone and in 8 after surgery.
  
  
  RESULTS
  Hypertension was associated with a significant increase in stroke volume and a non-significant increase in cardiac index. Blood pressure normalized after sprironolactone and after surgery in parallel with a significant decrease in blood volume.
  
  
  CONCLUSIONS
  These hemodynamic disorders in Conn's disease patients suggest that the increase in stroke volume is a consequence of increased venous return and more likely, in myocardium contractility or a combination of both.
  
  
  CONCLUSIONS
  These hemodynamic characteristics of Conn's disease should be useful in guiding monitoring schemes for these patients in the perioperative period.
authors.affiliation: Service de Médecine Interne, Hôpital Broussais, Paris.
authors.forename: G
authors.initials: G
authors.lastname: Amah
authors.forename: J
authors.initials: J
authors.lastname: Blacher
authors.forename: X
authors.initials: X
authors.lastname: Girerd
authors.forename: A
authors.initials: A
authors.lastname: Kheder
authors.forename: H
authors.initials: H
authors.lastname: Ben Maiz
authors.forename: M
authors.initials: M
authors.lastname: Safar
mesh_terms: D000293:Adolescent; D000328:Adult; D005260:Female; D006439:Hemodynamics / Q000187:drug effects; D006801:Humans; D006929:Hyperaldosteronism / Q000188:drug therapy / Q000503:physiopathology* / Q000601:surgery; D006973:Hypertension / Q000503:physiopathology; D008297:Male; D008875:Middle Aged; D000451:Mineralocorticoid Receptor Antagonists / Q000494:pharmacology* / Q000627:therapeutic use; D011184:Postoperative Period; D012964:Sodium / Q000502:physiology; D013148:Spironolactone / Q000494:pharmacology* / Q000627:therapeutic use
chemical_list: D000451:Mineralocorticoid Receptor Antagonists; D013148:Spironolactone; D012964:Sodium